Status:
RECRUITING
Fruquintinib Combined With TAS-102 in Refractory Metastatic Colorectal Cancer
Lead Sponsor:
Fudan University
Conditions:
Colorectal Cancer
Metastatic Colorectal Cancer
Eligibility:
All Genders
18-75 years
Brief Summary
Fruquintinib, as a standard treatment for refractory metastatic colorectal cancer (mCRC), has attracted increasing research efforts to explore its innovative strategies in combination with immunothera...
Eligibility Criteria
Inclusion
- Histology-confirmed metastatic CRC (mCRC)
- Disease progression on standard therapy with at least two lines of chemotherapy, including fluorouracil, oxaliplatin, and irinotecan with or without biologics such as bevacizumab and cetuximab
- Fruquintinib administered as salvage treatment
- Age: 18-75 years old
- Informed consent
Exclusion
- Liver or kidney dysfunction, or other conditions unsuitable for chemotherapy
- Fruquintinib and/or TAS-102 administration as second-line treatment
- Drug administration stopped after less than two cycles
Key Trial Info
Start Date :
January 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2024
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT06221423
Start Date
January 1 2020
End Date
May 31 2024
Last Update
January 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhongshan Hospital, Fudan University
Shanghai, Shanghai Municipality, China, 200032